Latest Cancer treatments Stories
CHICAGO, June 4, 2012 /PRNewswire/ -- Pharmacyclics, Inc (Nasdaq: PCYC) announced today updated results from three trials of Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). "This meeting at ASCO has been a continued affirmation of the promising activity and clinical benefit of ibrutinib in CLL. It will be exciting to move this toward definitive Phase III study...
INDIANAPOLIS, June 4, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results of a Phase II trial evaluating ALIMTA® (pemetrexed for injection) in combination with a platinum chemotherapy and radiation for patients with locally advanced non-small cell lung cancer (NSCLC). The findings will be presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. on June 4, 2012. "The current standard of care for many patients...
LUX-Lung 3 trial results highlighted at the official ASCO Press Conference: Afatinib* delays lung cancer progression compared to standard chemotherapy BURLINGTON, ON, June 4, 2012 /CNW/ - The LUX-Lung 3 Phase III results showed that lung cancer patients taking the novel compound afatinib*, an irreversible ErbB Family Blocker, as a first-line treatment, lived for almost one year before their disease progressed (progression-free survival (PFS) of 11.1 months) versus just over half...
(Ivanhoe Newswire) --Almost twelve million -- that’s how many cancer patients are living in the U.S. But what happens when the patients are no longer responsive to the drugs created to treat them? It’s a problem researchers at Case Western Reserve University are working to better understand. Researchers say overactive epidermal growth factor receptor (EGFR) signaling has been linked to the development of cancer. They found many patients have developed resistance to the drug therapies...
A clinical trial of an experimental new breast cancer treatment found that it extended the life expectancy of patients without the symptoms of the disease worsening, various media outlets reported on Sunday. The drug, TDM-1, is manufactured by Roche, and according to Naomi Kresge and Robert Langreth of Bloomberg, it works by carrying chemotherapy directly into cancer cells while successfully avoiding healthy ones, resulting in fewer side effects than conventional treatments. According...
RIDGEFIELD, Conn., June 4, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the company's pivotal Phase III clinical trial, LUX-Lung 3, investigating afatinib as a first-line treatment in patients with stage IIIb or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation, met its primary endpoint of progression-free survival (PFS). The study evaluated 345 patients with NSCLC across a variety of...
• Clinical Activity of Anti-PD-1 Published in New England Journal of Medicine (NEJM) and Presented at 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) • Phase 1 Data on Second Investigational Immunotherapy (Anti-PD-L1) Also Published in NEJM and Presented at ASCO Milwaukee, WI (PRWEB) June 02, 2012 SITC leaders publish landmark studies of new cancer immunotherapeutics Clinical activity of two cancer immunotherapeutic agents, anti-PD-1 and anti-PD-L1 were...
REDWOOD CITY, Calif., June 1, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of 18 studies being presented at the American Society for Clinical Oncology(®) (ASCO(®)) Annual Meeting taking place June 1-5 in Chicago, Illinois. New data includes validation of the Oncotype DX® colon cancer test in both stage II and stage III disease, the company's first prostate needle biopsy development study, and further evidence of the clinical value of the...
GAITHERSBURG, Md., May 31, 2012 /PRNewswire/ -- Zyngenia, Inc., a biopharmaceutical company developing Zybodies (next-generation multi-specific antibody-based drugs) in oncology and immunology, announced today that it has appointed Frank Hsu, M.D., as Chief Medical Officer (CMO) and a member of its executive team. Dr. Hsu is a medical oncologist and immunologist with deep academic and industry clinical research experience who most recently served as Senior Medical Director at...
SUNNYVALE, Calif., May 30, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its management is scheduled to present at the Jefferies Global Healthcare Conference in New York on Thursday, June 7, 2012 at 11:30 a.m. EDT/8:30 a.m. PDT. A live webcast of the presentations will be available online from the Investor Relations page of the Company's website at http://www.accuray.com. The webcast replay of the...
